- Home
- OSS vs AMRN Comparison
OSS vs AMRN Comparison
Compare OSS & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSS | AMRN |
|---|---|---|
| Founded | 1998 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.4M | 342.8M |
| IPO Year | 2017 | 1998 |
Fundamental Metrics
Financial Performance| Metric | OSS | AMRN |
|---|---|---|
| Price | $12.81 | $14.15 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | $10.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.3M | 82.2K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | $37,027,382.00 | ★ $181,104,000.00 |
| Revenue This Year | $22.19 | N/A |
| Revenue Next Year | $20.67 | $1.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 34.46 | ★ 39.22 |
| 52 Week Low | $4.17 | $12.96 |
| 52 Week High | $20.88 | $20.90 |
Technical Indicators
Market Signals| Indicator | OSS | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 37.36 | 34.02 |
| Support Level | $7.45 | $13.58 |
| Resistance Level | $20.79 | $14.49 |
| Average True Range (ATR) | 1.39 | 0.58 |
| MACD | -0.40 | -0.23 |
| Stochastic Oscillator | 16.99 | 3.60 |
Price Performance
Historical ComparisonAbout OSS One Stop Systems Inc.
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.